Michigan Cancer Research Consortium
Michigan Cancer Research Consortium List of component institutions
ABOUT MCRC-CCOP Active Clinical Trials About Clinical Trials Cancer Rsearch Info Resources & Links Member Area
Active Clinical Trials > Cancer Treatment and Symptom Management Trials

Active Clinical Trials: Lung- Miscellaneous

>> Go back to the list of categories
 
ProtocolTitle
SWOG-S0635A Phase II trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features (AdenoBAC) (1506)
  • Eligibility: click to view information

    Pts must have biopsy-proven, incompletely resected or unresectable BAC or BAC variants.
    No squamous ca in any histologic sample.
    No cytology specimens (bronchial brushings, washings, fine needle aspiration) as diagnosis of BAC/subtypes.
    Pts must be willing to provide prior smoking history. Pts who are never-smokers with BAC should be placed in S0636 if open at same institution.
    Pts must have selected St IIIB or St IV disease.
    Tumors may be multi focal or diffuse (see Sec. 5.3).
    Pts must have measurable and/or non-measurable disease documented by chest CT. Measurable disease must be assessed w/i 28days. Pleural effusions, ascites and lab parameters are not acceptable as only evidence of disease. Non-measurable disease must be assessed w/i 42 days.
    Pts must have a negative brain CT or MRI w/i 42 days; no brain mets.
    Pts may have rec?d prior RT completed at least 28 days prior to registration or palliative RT completed at lease 14 days prior to registration.
    Measurable or non-measurable disease must be present outside the previous radiation field or a new lesion inside the port must be present.
    Prior sx completed at least 28 days prior to registration is allowed.
    Pts must not have had a fine needle or core bx w/i 7 days.
    Pts may have rec?d systemic chemo (d/c w/i 28 days) or bio therapy. No prior tx with ZD1839, OSI-774, bevacizumab, or other EGFR or VEGF targeted tx. Pts must not have had hemoptysis >/= ½ tsp w/i 28 days.
    Pts must not have had clinical history of pulmonary/upper resp hemorrhage >/= Grade 2 w/i 6 months of Grade 1 w/i 28 days; no history of thrombosis or hemorrhage.
    No anticoagulation.
    Pts must have adequate hepatic function: bili Adequate renal function: serum creat /= 50 using formula in Sec 5.13.
    For UPC ratio >0.5, 24-hour urine protein must be obtained w/i 28 days and the level <1000 (use formula in Sec.5.14). ANC >/= 1,5000, platelet >/= 100,000.
    Controlled hypertension allowed.
    Pts must have PS 0-2,
    18 years or older.
    Pts strongly encouraged to submit specimens as outlined in Sec. 15.0.
    Pts must not be receiving or planning to receive sx or other non-protocol tx (including chemo, hormone, bio, or RT) directed at the BAC.
    Pts must not have serious non-healing wound, ulcer, or bone fx.
    No other prior malignancy except: treated basal cell or squamous cell skin ca, in situ cervical, Stage I or II ca in complete remission; disease-free from any ca for 5 years. No pregnant or nursing women.



  • HIPAA Forms: S0635 HIPAA
  • Consent Forms: S0635 Consent
Contact MCRC
Site Index
Site Feedback
View video Interview of Dr. Philip Stella
 
 
© 2010 MCRC. All rights reserved.